AustralieFrV1, Main, Exploration, bibRecord, 004D46

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Identifieur interne : 004D46 ( Main/Exploration ); précédent : 004D45; suivant : 004D47

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Auteurs : Tracy T. Batchelor [États-Unis] ; Paul Mulholland [Royaume-Uni] ; Bart Neyns [Belgique] ; L. Burt Nabors [États-Unis] ; Mario Campone [France] ; Antje Wick [Allemagne] ; Warren Mason [Canada] ; Tom Mikkelsen [États-Unis] ; Surasak Phuphanich [États-Unis] ; Lynn S. Ashby [États-Unis] ; John Degroot [États-Unis] ; Rao Gattamaneni [Royaume-Uni] ; Lawrence Cher [États-Unis] ; Mark Rosenthal [Australie] ; Franz Payer [Autriche] ; Juliane M. Jürgensmeier [États-Unis] ; Rakesh K. Jain [États-Unis] ; A. Gregory Sorensen [États-Unis] ; John Xu [États-Unis] ; QI LIU [États-Unis] ; Martin Van Den Bent [Pays-Bas]

Source :

Journal of clinical oncology [ 0732-183X ] ; 2013.

RBID : Pascal:13-0301224

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Agences internationales, Femelle, Glioblastome (mortalité), Glioblastome (traitement médicamenteux), Humains, Lomustine (administration et posologie), Mâle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Quinazolines (administration et posologie), Récidive tumorale locale (mortalité), Récidive tumorale locale (traitement médicamenteux), Taux de survie, Tumeurs du cerveau (mortalité), Tumeurs du cerveau (traitement médicamenteux), Études de suivi.
MESH :
- administration et posologie : Lomustine, Quinazolines.
- mortalité : Glioblastome, Récidive tumorale locale, Tumeurs du cerveau.
- traitement médicamenteux : Glioblastome, Récidive tumorale locale, Tumeurs du cerveau.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
Pascal (Inist)
- Adulte d'âge moyen, Agences internationales, Essai clinique phase III, Femelle, Humains, Mâle, Pronostic, Randomisation, Etude comparative, Cédiranib, Efficacité traitement, Association médicamenteuse, Chimiothérapie, Homme, Récidive, Lomustine, Cancérologie, Glioblastome, Antiangiogénique, Anticancéreux, Monothérapie, Taux de survie, Études de suivi.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiangiogenic agent, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Antineoplastic agent, Brain Neoplasms (drug therapy), Brain Neoplasms (mortality), Cancerology, Cediranib, Chemotherapy, Comparative study, Drug combination, Female, Follow-Up Studies, Glioblastoma, Glioblastoma (drug therapy), Glioblastoma (mortality), Human, Humans, International Agencies, Lomustine, Lomustine (administration & dosage), Male, Middle Aged, Monotherapy, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (mortality), Phase III trial, Prognosis, Quinazolines (administration & dosage), Randomization, Relapse, Survival Rate, Treatment efficiency.
MESH :
- chemical , administration & dosage : Lomustine, Quinazolines.
- drug therapy : Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local.
- mortality : Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Female, Follow-Up Studies, Humans, International Agencies, Male, Middle Aged, Prognosis, Survival Rate.

Abstract

Purpose A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma. Patients and Methods Patients (N = 325) with recurrent glioblastoma who previously received radiation and temozolomide were randomly assigned 2:2:1 to receive (1) cediranib (30 mg) monotherapy; (2) cediranib (20 mg) plus lomustine (110 mg/m²); (3) lomustine (110 mg/m²) plus a placebo. The primary end point was progression-free survival based on blinded, independent radiographic assessment of postcontrast T1-weighted and noncontrast T2-weighted magnetic resonance imaging (MRI) brain scans. Results The primary end point of progression-free survival (PFS) was not significantly different for either cediranib alone (hazard ratio [HR] = 1.05; 95% CI, 0.74 to 1.50; two-sided P = .90) or cediranib in combination with lomustine (HR = 0.76; 95% CI, 0.53 to 1.08; two-sided P = .16) versus lomustine based on independent or local review of postcontrast T1-weighted MRI. Conclusion This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021043

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma</title>
<author><name sortKey="Batchelor, Tracy T" sort="Batchelor, Tracy T" uniqKey="Batchelor T" first="Tracy T." last="Batchelor">Tracy T. Batchelor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mulholland, Paul" sort="Mulholland, Paul" uniqKey="Mulholland P" first="Paul" last="Mulholland">Paul Mulholland</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
<settlement type="city">Londres</settlement>
</placeName>
<orgName type="university">University College de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Universitair Ziekenhuis Brussel</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burt Nabors, L" sort="Burt Nabors, L" uniqKey="Burt Nabors L" first="L." last="Burt Nabors">L. Burt Nabors</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Alabama at Birmingham</s1>
<s2>Birmingham, AL</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Alabama at Birmingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Centre Rene Gauducheau</s1>
<s2>Saint-Herblain</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Saint-Herblain</wicri:noRegion>
<wicri:noRegion>Centre Rene Gauducheau</wicri:noRegion>
<wicri:noRegion>Centre Rene Gauducheau</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wick, Antje" sort="Wick, Antje" uniqKey="Wick A" first="Antje" last="Wick">Antje Wick</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>University of Heidelberg</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mikkelsen, Tom" sort="Mikkelsen, Tom" uniqKey="Mikkelsen T" first="Tom" last="Mikkelsen">Tom Mikkelsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Henry Ford Hospital</s1>
<s2>Detroit, MI</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Henry Ford Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phuphanich, Surasak" sort="Phuphanich, Surasak" uniqKey="Phuphanich S" first="Surasak" last="Phuphanich">Surasak Phuphanich</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Cedars-Sinai Medical Center</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cedars-Sinai Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ashby, Lynn S" sort="Ashby, Lynn S" uniqKey="Ashby L" first="Lynn S." last="Ashby">Lynn S. Ashby</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Barrow Neurological Institute</s1>
<s2>Phoenix, AZ</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Barrow Neurological Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Degroot, John" sort="Degroot, John" uniqKey="Degroot J" first="John" last="Degroot">John Degroot</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gattamaneni, Rao" sort="Gattamaneni, Rao" uniqKey="Gattamaneni R" first="Rao" last="Gattamaneni">Rao Gattamaneni</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Christie Foundation Trust Hospital</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cher, Lawrence" sort="Cher, Lawrence" uniqKey="Cher L" first="Lawrence" last="Cher">Lawrence Cher</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Austin Health Cancer Services</s1>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Austin Health Cancer Services</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Royal Melbourne Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Payer, Franz" sort="Payer, Franz" uniqKey="Payer F" first="Franz" last="Payer">Franz Payer</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Medical University</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Medical University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jurgensmeier, Juliane M" sort="Jurgensmeier, Juliane M" uniqKey="Jurgensmeier J" first="Juliane M." last="Jürgensmeier">Juliane M. Jürgensmeier</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jain, Rakesh K" sort="Jain, Rakesh K" uniqKey="Jain R" first="Rakesh K." last="Jain">Rakesh K. Jain</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregory Sorensen, A" sort="Gregory Sorensen, A" uniqKey="Gregory Sorensen A" first="A." last="Gregory Sorensen">A. Gregory Sorensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xu, John" sort="Xu, John" uniqKey="Xu J" first="John" last="Xu">John Xu</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Qi Liu" sort="Qi Liu" uniqKey="Qi Liu" last="Qi Liu">QI LIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Bent, Martin" sort="Van Den Bent, Martin" uniqKey="Van Den Bent M" first="Martin" last="Van Den Bent">Martin Van Den Bent</name>
<affiliation wicri:level="3"><inist:fA14 i1="17"><s1>Erasmus University Medical Center-Daniel den Hoed Cancer Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0301224</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0301224 INIST</idno>
<idno type="RBID">Pascal:13-0301224</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000827</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005661</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000723</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000723</idno>
<idno type="wicri:doubleKey">0732-183X:2013:Batchelor T:phase:iii:randomized</idno>
<idno type="wicri:Area/Main/Merge">004E97</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021043</idno>
<idno type="RBID">PMC:4021043</idno>
<idno type="wicri:Area/Pmc/Corpus">001953</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001953</idno>
<idno type="wicri:Area/Pmc/Curation">001812</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001812</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001956</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001956</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">003B20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B20</idno>
<idno type="wicri:Area/PubMed/Curation">003990</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003990</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003990</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003990</idno>
<idno type="wicri:Area/Ncbi/Merge">001406</idno>
<idno type="wicri:Area/Ncbi/Curation">001406</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001406</idno>
<idno type="wicri:doubleKey">0732-183X:2013:Batchelor T:phase:iii:randomized</idno>
<idno type="wicri:Area/Main/Merge">004649</idno>
<idno type="wicri:Area/Main/Curation">004D46</idno>
<idno type="wicri:Area/Main/Exploration">004D46</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma</title>
<author><name sortKey="Batchelor, Tracy T" sort="Batchelor, Tracy T" uniqKey="Batchelor T" first="Tracy T." last="Batchelor">Tracy T. Batchelor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mulholland, Paul" sort="Mulholland, Paul" uniqKey="Mulholland P" first="Paul" last="Mulholland">Paul Mulholland</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
<settlement type="city">Londres</settlement>
</placeName>
<orgName type="university">University College de Londres</orgName>
</affiliation>
</author>
<author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Universitair Ziekenhuis Brussel</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burt Nabors, L" sort="Burt Nabors, L" uniqKey="Burt Nabors L" first="L." last="Burt Nabors">L. Burt Nabors</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Alabama at Birmingham</s1>
<s2>Birmingham, AL</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Alabama at Birmingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Centre Rene Gauducheau</s1>
<s2>Saint-Herblain</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Saint-Herblain</wicri:noRegion>
<wicri:noRegion>Centre Rene Gauducheau</wicri:noRegion>
<wicri:noRegion>Centre Rene Gauducheau</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wick, Antje" sort="Wick, Antje" uniqKey="Wick A" first="Antje" last="Wick">Antje Wick</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>University of Heidelberg</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mikkelsen, Tom" sort="Mikkelsen, Tom" uniqKey="Mikkelsen T" first="Tom" last="Mikkelsen">Tom Mikkelsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Henry Ford Hospital</s1>
<s2>Detroit, MI</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Henry Ford Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phuphanich, Surasak" sort="Phuphanich, Surasak" uniqKey="Phuphanich S" first="Surasak" last="Phuphanich">Surasak Phuphanich</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Cedars-Sinai Medical Center</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cedars-Sinai Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ashby, Lynn S" sort="Ashby, Lynn S" uniqKey="Ashby L" first="Lynn S." last="Ashby">Lynn S. Ashby</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Barrow Neurological Institute</s1>
<s2>Phoenix, AZ</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Barrow Neurological Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Degroot, John" sort="Degroot, John" uniqKey="Degroot J" first="John" last="Degroot">John Degroot</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Anderson Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gattamaneni, Rao" sort="Gattamaneni, Rao" uniqKey="Gattamaneni R" first="Rao" last="Gattamaneni">Rao Gattamaneni</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Christie Foundation Trust Hospital</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cher, Lawrence" sort="Cher, Lawrence" uniqKey="Cher L" first="Lawrence" last="Cher">Lawrence Cher</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Austin Health Cancer Services</s1>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Austin Health Cancer Services</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Royal Melbourne Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Payer, Franz" sort="Payer, Franz" uniqKey="Payer F" first="Franz" last="Payer">Franz Payer</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Medical University</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Medical University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jurgensmeier, Juliane M" sort="Jurgensmeier, Juliane M" uniqKey="Jurgensmeier J" first="Juliane M." last="Jürgensmeier">Juliane M. Jürgensmeier</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jain, Rakesh K" sort="Jain, Rakesh K" uniqKey="Jain R" first="Rakesh K." last="Jain">Rakesh K. Jain</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregory Sorensen, A" sort="Gregory Sorensen, A" uniqKey="Gregory Sorensen A" first="A." last="Gregory Sorensen">A. Gregory Sorensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Massachusetts General Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Massachusetts General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xu, John" sort="Xu, John" uniqKey="Xu J" first="John" last="Xu">John Xu</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Qi Liu" sort="Qi Liu" uniqKey="Qi Liu" last="Qi Liu">QI LIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>AstraZeneca</s1>
<s2>Wilmington, DE</s2>
<s3>USA</s3>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>AstraZeneca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Bent, Martin" sort="Van Den Bent, Martin" uniqKey="Van Den Bent M" first="Martin" last="Van Den Bent">Martin Van Den Bent</name>
<affiliation wicri:level="3"><inist:fA14 i1="17"><s1>Erasmus University Medical Center-Daniel den Hoed Cancer Center</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiangiogenic agent</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Antineoplastic agent</term>
<term>Brain Neoplasms (drug therapy)</term>
<term>Brain Neoplasms (mortality)</term>
<term>Cancerology</term>
<term>Cediranib</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Drug combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Glioblastoma</term>
<term>Glioblastoma (drug therapy)</term>
<term>Glioblastoma (mortality)</term>
<term>Human</term>
<term>Humans</term>
<term>International Agencies</term>
<term>Lomustine</term>
<term>Lomustine (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Monotherapy</term>
<term>Neoplasm Recurrence, Local (drug therapy)</term>
<term>Neoplasm Recurrence, Local (mortality)</term>
<term>Phase III trial</term>
<term>Prognosis</term>
<term>Quinazolines (administration & dosage)</term>
<term>Randomization</term>
<term>Relapse</term>
<term>Survival Rate</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Agences internationales</term>
<term>Femelle</term>
<term>Glioblastome (mortalité)</term>
<term>Glioblastome (traitement médicamenteux)</term>
<term>Humains</term>
<term>Lomustine (administration et posologie)</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Quinazolines (administration et posologie)</term>
<term>Récidive tumorale locale (mortalité)</term>
<term>Récidive tumorale locale (traitement médicamenteux)</term>
<term>Taux de survie</term>
<term>Tumeurs du cerveau (mortalité)</term>
<term>Tumeurs du cerveau (traitement médicamenteux)</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Lomustine</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Lomustine</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Brain Neoplasms</term>
<term>Glioblastoma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Brain Neoplasms</term>
<term>Glioblastoma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Glioblastome</term>
<term>Récidive tumorale locale</term>
<term>Tumeurs du cerveau</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Glioblastome</term>
<term>Récidive tumorale locale</term>
<term>Tumeurs du cerveau</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>International Agencies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Agences internationales</term>
<term>Essai clinique phase III</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Randomisation</term>
<term>Etude comparative</term>
<term>Cédiranib</term>
<term>Efficacité traitement</term>
<term>Association médicamenteuse</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Récidive</term>
<term>Lomustine</term>
<term>Cancérologie</term>
<term>Glioblastome</term>
<term>Antiangiogénique</term>
<term>Anticancéreux</term>
<term>Monothérapie</term>
<term>Taux de survie</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma. Patients and Methods Patients (N = 325) with recurrent glioblastoma who previously received radiation and temozolomide were randomly assigned 2:2:1 to receive (1) cediranib (30 mg) monotherapy; (2) cediranib (20 mg) plus lomustine (110 mg/m<sup>2</sup>
); (3) lomustine (110 mg/m<sup>2</sup>
) plus a placebo. The primary end point was progression-free survival based on blinded, independent radiographic assessment of postcontrast T1-weighted and noncontrast T2-weighted magnetic resonance imaging (MRI) brain scans. Results The primary end point of progression-free survival (PFS) was not significantly different for either cediranib alone (hazard ratio [HR] = 1.05; 95% CI, 0.74 to 1.50; two-sided P = .90) or cediranib in combination with lomustine (HR = 0.76; 95% CI, 0.53 to 1.08; two-sided P = .16) versus lomustine based on independent or local review of postcontrast T1-weighted MRI. Conclusion This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Belgique</li>
<li>Canada</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>District de Karlsruhe</li>
<li>Grand Londres</li>
<li>Grand Manchester</li>
<li>Hollande-Méridionale</li>
<li>Région de Bruxelles-Capitale</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Bruxelles</li>
<li>Heidelberg</li>
<li>Londres</li>
<li>Manchester</li>
<li>Melbourne</li>
<li>Rotterdam</li>
</settlement>
<orgName><li>University College de Londres</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Batchelor, Tracy T" sort="Batchelor, Tracy T" uniqKey="Batchelor T" first="Tracy T." last="Batchelor">Tracy T. Batchelor</name>
</noRegion>
<name sortKey="Ashby, Lynn S" sort="Ashby, Lynn S" uniqKey="Ashby L" first="Lynn S." last="Ashby">Lynn S. Ashby</name>
<name sortKey="Burt Nabors, L" sort="Burt Nabors, L" uniqKey="Burt Nabors L" first="L." last="Burt Nabors">L. Burt Nabors</name>
<name sortKey="Cher, Lawrence" sort="Cher, Lawrence" uniqKey="Cher L" first="Lawrence" last="Cher">Lawrence Cher</name>
<name sortKey="Degroot, John" sort="Degroot, John" uniqKey="Degroot J" first="John" last="Degroot">John Degroot</name>
<name sortKey="Gregory Sorensen, A" sort="Gregory Sorensen, A" uniqKey="Gregory Sorensen A" first="A." last="Gregory Sorensen">A. Gregory Sorensen</name>
<name sortKey="Jain, Rakesh K" sort="Jain, Rakesh K" uniqKey="Jain R" first="Rakesh K." last="Jain">Rakesh K. Jain</name>
<name sortKey="Jurgensmeier, Juliane M" sort="Jurgensmeier, Juliane M" uniqKey="Jurgensmeier J" first="Juliane M." last="Jürgensmeier">Juliane M. Jürgensmeier</name>
<name sortKey="Mikkelsen, Tom" sort="Mikkelsen, Tom" uniqKey="Mikkelsen T" first="Tom" last="Mikkelsen">Tom Mikkelsen</name>
<name sortKey="Phuphanich, Surasak" sort="Phuphanich, Surasak" uniqKey="Phuphanich S" first="Surasak" last="Phuphanich">Surasak Phuphanich</name>
<name sortKey="Qi Liu" sort="Qi Liu" uniqKey="Qi Liu" last="Qi Liu">QI LIU</name>
<name sortKey="Xu, John" sort="Xu, John" uniqKey="Xu J" first="John" last="Xu">John Xu</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Mulholland, Paul" sort="Mulholland, Paul" uniqKey="Mulholland P" first="Paul" last="Mulholland">Paul Mulholland</name>
</region>
<name sortKey="Gattamaneni, Rao" sort="Gattamaneni, Rao" uniqKey="Gattamaneni R" first="Rao" last="Gattamaneni">Rao Gattamaneni</name>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name>
</region>
</country>
<country name="France"><noRegion><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Wick, Antje" sort="Wick, Antje" uniqKey="Wick A" first="Antje" last="Wick">Antje Wick</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name>
</noRegion>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
</region>
</country>
<country name="Autriche"><noRegion><name sortKey="Payer, Franz" sort="Payer, Franz" uniqKey="Payer F" first="Franz" last="Payer">Franz Payer</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Van Den Bent, Martin" sort="Van Den Bent, Martin" uniqKey="Van Den Bent M" first="Martin" last="Van Den Bent">Martin Van Den Bent</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D46 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D46 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0301224
   |texte=   Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.